Seer, Inc. (SEER)
NASDAQ (NGS) NASDAQ (NGS) Primary Summary
Seer Q1 Earnings Call Highlights
Seer NASDAQ: SEER reported lower first-quarter revenue but reaffirmed its full-year 2026 outlook, with management pointing to population-scale proteomics studies, an expanding publication base and expected second-half consumables demand as supports for the year.
Seer, Inc. (SEER) Q1 2026 Earnings Call Transcript
Seer, Inc. (SEER) Q1 2026 Earnings Call Transcript
Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
Seer, Inc. (SEER) Q4 2025 Earnings Call Transcript
Seer, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
 Point72 Asset Management LP Point72 Asset Management LP | 14,813 | $27,107.92 | $31,847.95 | $4,740.03 | 17.49% |
| HFT Hui Fai Tam Caitong International Asset Management Co. Ltd. | 3 | $5 | $6.49 | $1.49 | 29.8% |
 Raymond Debbane Siren, L.L.C. | 2.46M | $4.84M | $5.32M | $479,441.23 | 9.9% |
| RJ Rebecca Judd Pathstone Holdings, LLC | 28,205 | $47,667 | $60,922.8 | $13,255.8 | 27.81% |
| PLC Peapod Lane Capital LLC Peapod Lane Capital LLC | 438,581 | $1.01M | $949,527.86 | -$60,423.56 | -5.98% |
Seer, Inc. (SEER) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Seer, Inc. ever had a stock split?
Seer, Inc. Profile
| Biotechnology Industry | Healthcare Sector | Omid C. Farokhzad CEO | NASDAQ (NGS) Exchange | 81578P106 CUSIP |
| US Country | 124 Employees | - Last Dividend | - Last Split | 4 Dec 2020 IPO Date |
Overview
Seer, Inc. is a pioneering life sciences company dedicated to enhancing our understanding of the proteome's complex biology. Proteomics, the study of proteins, is crucial for comprehending biological systems and disease mechanisms, offering vast potential for innovations in healthcare and disease treatment. Established in 2017 and headquartered in Redwood City, California, Seer, Inc. embarked on its mission to revolutionize proteomic analysis with advanced technological solutions. Initially known as Seer Biosciences, Inc., the company underwent a rebranding to Seer, Inc. in July 2018, marking a significant milestone in its journey. With operations spanning across China, Australia, Eastern Europe, Israel, and Japan, Seer, Inc. aims to make its innovative solutions accessible to a global audience. The company's target market includes academic institutions, life sciences, and research laboratories, along with biopharmaceutical and biotechnology companies. These entities utilize Seer's products for non-diagnostic and non-clinical research purposes, contributing to the expansion of knowledge within the scientific community.
Products and Services
- Proteograph Product Suite
At the core of Seer, Inc.'s offerings is the Proteograph Product Suite, an integrated array of products designed to elevate proteomic analysis to new heights. This suite encompasses proprietary engineered nanoparticles and consumables, complemented by automation instrumentation and sophisticated software. The Proteograph Product Suite stands out for its ability to perform comprehensive proteomic analyses, making it a vital tool for research laboratories globally. Its design caters to the needs of virtually any lab, ensuring seamless integration into existing research workflows. Primarily intended for research use only, this suite equips scientists and researchers with the means to delve deeper into the proteome, unveiling insights that were previously beyond reach. By democratizing access to high-quality proteomic data, Seer, Inc. facilitates groundbreaking discoveries in biology, medicine, and pharmacology.
